Словения - словенски - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

actavis group ptc ehf. - perindopril - tableta - perindopril 1,67 mg / 1 tableta - perindopril

Словения - словенски - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

actavis group ptc ehf. - perindopril - tableta - perindopril 3,34 mg / 1 tableta - perindopril

Словения - словенски - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

actavis group ptc ehf. - perindopril - tableta - perindopril 6,68 mg / 1 tableta - perindopril

Словения - словенски - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

servier pharma d.o.o. - ivabradin, metoprololijev tartrat - filmsko obložena tableta - ivabradin 7,5 mg / 1 tableta; metoprololijev tartrat 50 mg / 1 tableta - metoprolol in ivabradin

Европейски съюз - словенски - EMA (European Medicines Agency)

sandoz gmbh - aripiprazol - schizophrenia; bipolar disorder - psiholeptiki - aripiprazol sandoz je indiciran za zdravljenje shizofrenije pri odraslih in pri mladostnikih, starih 15 let ali več. aripiprazole sandoz je primerna za zdravljenje zmerno do hudo manične epizode v bipolarne motnje i bolezni in za preprečevanje novo manično epizodo pri odraslih, ki so imeli pretežno manične epizode in katerih manične epizode se odzvali na zdravljenje aripiprazole. aripiprazole sandoz je primerna za zdravljenje do 12 tednov, z zmerno do hudo manične epizode v bipolarne motnje i motnje pri mladostnikih, ki so stari 13 let in starejši.

Словения - словенски - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

fresenius kabi oncology plc - anastrozol - filmsko obložena tableta - anastrozol 1 mg / 1 tableta - anastrozol

Словения - словенски - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

alkaloid - int d.o.o. - cefpodoksim - filmsko obložena tableta - cefpodoksim 100 mg / 1 tableta - cefpodoksim

Словения - словенски - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sandoz d.d. - sildenafil - filmsko obložena tableta - sildenafil 20 mg / 1 tableta - sildenafil

Словения - словенски - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

alkaloid - int d.o.o. - cefpodoksim - filmsko obložena tableta - cefpodoksim 100 mg / 1 tableta - cefpodoksim

Европейски съюз - словенски - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - antineoplastična sredstva - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.  yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 in 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.